血清LDH和β2-MG水平与原发骨非霍奇金淋巴瘤预后关系  

THE PROGNOSTIC VALUE OF SERUM LDH AND β2-MG IN PATIENTS WITH PRIMARY NON-HODGKIN'S LYMPHOMA OF BONE

作　　者：苗玉迪[1] 王磊[2] 王晖[1] 连小云[1] 王一[1] 王岐山[1] 

机构地区：[1]陕西省人民医院血液科,陕西西安710068 [2]西安交通大学第二附属医院骨科

出　　处：《泸州医学院学报》2010年第4期361-363,共3页Journal of Luzhou Medical College

摘　　要：目的:探讨血清中乳酸脱氢酶(LDH)与β2微球蛋白(β2-MG)水平与原发骨非霍奇金淋巴瘤(PLB)预后的关系。方法:分别采用速率法和免疫比浊法测定67例PLB患者血清LDH和β2-MG值。结果:Ⅳ期或高度恶性PLB患者与Ⅰ期或中、低度恶性PLB患者血清LDH和β2-MG测定值有显著性差异(P<0.05);PLB患者血清LDH和β2-MG测定值正常组的3年、5年、10年生存率、缓解率明显高于测定值升高组,差异有统计学意义(P<0.05)。结论:血清LDH和β2-MG水平可作为PLB患者分期、预后的辅助指标。Objective： To evaluate the prognostic value of serum lactic dehydrogenate （LDH） and β2 -Microglobulin （β2 -MG） in primary non-Hodgkin＇s lymphoma of bone （PLB） patients. Methods： The serum LDH and β2-MG of 67 PLB patients were measured by rate method and radioimmunoassay respectively. Results： The LDH and β2-MG level had significant differences （P〈0.05） between high grade group and intermediate grade group.The 3-year, 5-year,10-year survival and alleviation rate of patients with normal LDH and β2-MG level were obviously higher than those with increasing LDH and β2-MG level. Difference is of significance （P〈0.05）. Conclusion： The level of LDH and β2-MG can be taken as an auxiliary clinical indicator to classify the phase and to predict the prognosis in PLB patients.

关 键 词：原发骨非霍奇金淋巴瘤 乳酸脱氢酶 Β2微球蛋白 预后 

分 类 号：R733[医药卫生—肿瘤]